İmmünsüpresif tedavi alacak hastalarda hepatit serolojisi
Yükleniyor...
Tarih
2020
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Harran Üniversitesi Tıp Fakültesi Dekanlığı
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Amaç: İmmünsupresif ilaç kullananlarda, hepatit B reaktivasyon riskine yönelik tarama yapılması önerilmektedir.Bu çalışmada immünsüpresif tedavi öncesi, Enfeksiyon hastalıkları kliniğine yönlendirilen hastalarda hepatit Bvirüsü (HBV), hepatit C virüsü (HCV) ve hepatit A virüsü (HAV) sonuçları retrospektif olarak irdelenmesiamaçlandı.Materyal ve Metod: Çalışmamızda Ocak 2018 - Aralık 2018 tarihleri arasında immünsüpresif tedavi öncesi,Enfeksiyon hastalıkları kliniğine yönlendirilen 148 hastanın hepatit B yüzey antijeni (HBsAg), hepatit B yüzeyantikoru (Anti-HBs), hepatit B core protein antikoru (Anti-HBc IgG), anti hepatit C virüs antikoru (Anti-HCV) ve antihepatit A virüs antikoru (Anti-HAV) hasta dosyalarından ve hastane otomasyon sisteminden retrospektif olarakincelendi.Bulgular: HBsAg pozitiflik oranı %4,1, Anti-HBs pozitiflik oranı %31,8, İzole Anti-HBc IgG pozitiflik oranı %1,4 veiki hastada ise Anti-HBs bakılmamıştı. Anti-HCV pozitifliği %1,4 tespit edildi. Hastaların %79,7 Anti-HAVbakılmamış, Anti-HAV pozitifliği %12,2 ve Anti-HAV negatifliği %8,1 olarak saptandı.Sonuç: İmmünsüpresif tedavi öncesi tarama yapılmasına rağmen bazı taramaların eksik yapıldığı tespit edildi.Bu nedenle bu hastaları takip eden hekimlere eğitim verilmesi ve özellikle HBV enfeksiyonu konusunda farkındalıkoluşturulmasını önermekteyiz.
Background: Screening aimed at hepatitis B reactivation risk is recommended in patients using immunosuppressive drugs. The aim of this study was to investigate the results of hepatitis B virus (HBV), hepatitis C virus (HCV) and hepatitis A virus (HAV) retrospectively in patients referred to the infectious diseases clinic before immunosuppressive treatment. Materials and Methods: In our study, 148 patients who were referred to our infectious disease clinic before immunosuppressive therapeutic usage between January 2018-December 2018. Patients files and hospital automation sysytem were analyzed for Hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (AntiHBs), hepatitis B core protein antibody (Anti -HBc IgG), anti-hepatitis C virus antibody (Anti-HCV) and antihepatitis A virus antibody (anti -HAV) retrospectively. Results: HbsAg positivity rate was 4.1%, Anti-HBs positivity rate was 31.8%, Isolated Anti-HBc IgG positivity rate was 1.4% and Anti-HBs was not detected in two patients. Anti-HCV positivity was detected as 1.4%. Anti-HAV was not examined in 79.7% of the patients, 12.2% was determined to have positive Anti-HAV and 8.1% negative Anti-HAV. Conclusions: Since some screenings are incomplete despite screening performed for the patients, we recommend that physicians who follow patients receiving immunosuppressive therapy should be trained and raise awareness of HBV infection.
Background: Screening aimed at hepatitis B reactivation risk is recommended in patients using immunosuppressive drugs. The aim of this study was to investigate the results of hepatitis B virus (HBV), hepatitis C virus (HCV) and hepatitis A virus (HAV) retrospectively in patients referred to the infectious diseases clinic before immunosuppressive treatment. Materials and Methods: In our study, 148 patients who were referred to our infectious disease clinic before immunosuppressive therapeutic usage between January 2018-December 2018. Patients files and hospital automation sysytem were analyzed for Hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (AntiHBs), hepatitis B core protein antibody (Anti -HBc IgG), anti-hepatitis C virus antibody (Anti-HCV) and antihepatitis A virus antibody (anti -HAV) retrospectively. Results: HbsAg positivity rate was 4.1%, Anti-HBs positivity rate was 31.8%, Isolated Anti-HBc IgG positivity rate was 1.4% and Anti-HBs was not detected in two patients. Anti-HCV positivity was detected as 1.4%. Anti-HAV was not examined in 79.7% of the patients, 12.2% was determined to have positive Anti-HAV and 8.1% negative Anti-HAV. Conclusions: Since some screenings are incomplete despite screening performed for the patients, we recommend that physicians who follow patients receiving immunosuppressive therapy should be trained and raise awareness of HBV infection.
Açıklama
Anahtar Kelimeler
İmmünsüpresyon, HBV, HCV, HAV, Immunosuppression
Kaynak
Harran Üniversitesi Tıp Fakültesi Dergisi
WoS Q Değeri
Scopus Q Değeri
Cilt
17
Sayı
1
Künye
ÇABALAK M, BAL T, OCAK S (2020). İmmünsüpresif Tedavi Alacak Hastalarda Hepatit Serolojisi. Harran Üniversitesi Tıp Fakültesi Dergisi, 17(1), 70 - 73. 10.35440/hutfd.666188
